Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?
Gynecol Oncol
; 116(3): 395-8, 2010 Mar.
Article
en En
| MEDLINE
| ID: mdl-20042226
ABSTRACT
OBJECTIVE:
To investigate if the use of diagnostic FDG-PET/CT leads to stage migration in patients with advanced ovarian cancer and to evaluate the prognostic significance of FDG-PET/CT.METHODS:
From September 2004 to August 2007, 201 patients with a Risk of Malignancy Index (RMI) >150 based on serum CA-125, ultrasound examinations and menopausal state, underwent PET/CT within 2 weeks prior to standard surgery/debulking of a pelvic tumor. On 15 August, 2009 overall survival and prognostic variables were analysed in 66 ovarian cancer patients (64 stage III and 2 stage IV).RESULTS:
Median follow-up was 30.2 months; median age was 62.5 years (range 35-85 years); 97% (64/66) had a performance statusCONCLUSION:
In primary advanced ovarian cancer the use of diagnostic FDG-PET/CT leads to stage migration. Adequate staging is the foundation for ovarian cancer treatment and advanced imaging for optimal evaluation of metastases should be promoted in clinical trials. The strongest determinant of patient outcome is residual abdominal tumor after primary surgery.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Radiofármacos
/
Fluorodesoxiglucosa F18
/
Tomografía de Emisión de Positrones
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Gynecol Oncol
Año:
2010
Tipo del documento:
Article
País de afiliación:
Dinamarca